Jakob Riis

Jakob Riis holds a Master's degree in Forestry and PhD in Econometrics from The Royal Veterinary and Agricultural University. He was born in 1966 and is a Danish citizen. He was nominated for election to H. Lundbeck A/S' Board of Directors at the 2023 Annual General Meeting. He is a member of H. Lundbeck A/S' Scientific Committee.

Jakob Riis is currently the CEO at Falck A/S and is considered as non-independent Lundbeck Board member, as the Lundbeck Foundation is a significant shareholder in the company.

Jakob Riis has more than 25 years of experience in management and sales & marketing in the international healthcare industry. He previously worked at Novo Nordisk for 20 years in various positions in the commercial area (U.S. sales organization, Japan, Head of Marketing for more than a decade, and most recent as President of the North American business, member of the Executive Management).

Jakob’s special qualifications for serving on H. Lundbeck A/S’ Board of Directors include proven track record in pharmaceutical value chain management from early-stage assets, production planning, registration trials, label negotiations, market access and global commercialization. In addition, he has extensive experience in operating in a listed company and market communication.